Fielder Capital Group LLC Sells 171 Shares of Merck & Co., Inc. $MRK

Fielder Capital Group LLC decreased its position in Merck & Co., Inc. (NYSE:MRK) by 5.1% during the second quarter, Holdings Channel.com reports. The fund owned 3,153 shares of the company’s stock after selling 171 shares during the quarter. Fielder Capital Group LLC’s holdings in Merck & Co., Inc. were worth $250,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of MRK. Little House Capital LLC raised its position in Merck & Co., Inc. by 1.2% during the 2nd quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock valued at $1,998,000 after purchasing an additional 308 shares during the last quarter. Semus Wealth Partners LLC increased its stake in shares of Merck & Co., Inc. by 8.2% during the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock valued at $452,000 after buying an additional 382 shares during the period. Longfellow Investment Management Co. LLC raised its holdings in shares of Merck & Co., Inc. by 20.4% during the first quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock valued at $1,739,000 after acquiring an additional 3,282 shares in the last quarter. Quilter Plc raised its holdings in shares of Merck & Co., Inc. by 5.6% during the first quarter. Quilter Plc now owns 1,180,797 shares of the company’s stock valued at $105,988,000 after acquiring an additional 62,933 shares in the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lifted its stake in Merck & Co., Inc. by 9.8% in the second quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after acquiring an additional 79,529 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on MRK shares. Weiss Ratings reissued a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Morgan Stanley cut their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Berenberg Bank downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price target for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. Wells Fargo & Company cut their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. Finally, Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Hold” and a consensus price target of $104.33.

Merck & Co., Inc. Stock Up 0.4%

Shares of Merck & Co., Inc. stock opened at $87.54 on Friday. The stock has a market capitalization of $218.65 billion, a PE ratio of 13.49, a price-to-earnings-growth ratio of 0.96 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The company has a 50-day simple moving average of $84.43 and a two-hundred day simple moving average of $81.54. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $106.49.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.10. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The business had revenue of $15.81 billion for the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.